Author(s)

Wei Zhao, Xin Shi, Zhiliang Cong, Liang Guo

Corresponding Author

Liang Guo

Abstract

To investigate the relationship between the expression of beta-tubulin III and the efficacy of docetaxel in advanced gastric cancer. Pathological data of patients with advanced gastric cancer treated with docetaxel-based chemotherapy regimen were examined by immunohistochemical PV9000 method. The relationship between the expression of beta-tubulin III and the efficacy and adverse reactions of chemotherapy was analyzed. Patients with TUBB3 (-) expression were better than those with TUBB3 (+). The most common adverse reactions were bone marrow suppression and digestive tract reaction. The patients with TUBB3 (-) expression were well tolerated after symptomatic support treatment. There was no significant difference in toxic and side effects between TUBB3 (+) group and TUBB3 (-) group. This study shows that the expression of TUBB3 may be a predictor of the efficacy of docetaxel-based chemotherapy regimens in the treatment of advanced gastric cancer.

Keywords

TUBB3 gene expression, Chemotherapy, Docetaxel, Gastric cancer